Lista de verificación de documentación de péptidos: Guía de preparación para la votación de la FDA

que julio 2026 El voto cambió y no cambió

en julio 23-24, 2026, El Comité Asesor de Composición Farmacéutica revisó siete péptidos no aprobados y recomendó seis de ellos para la lista a granel 503A. (McDermott Will & Esmeril, 2026-07-28). BPC-157, KPV, y TB-500 cada uno aprobado 8-6 con una abstención; ITV-c aprobadas 7-5; Semax pasó 8-5; epitalon pasó 7-4; Emideltide (DSIP) fallido 6-7. RAPOS registró el recuento de Epitalon como 7-5, así que trata esa única figura como inestable.

⚠️ Advertencia: La recomendación es sólo consultiva.. Como Mintz notas, un voto consultivo no es una acción de agencia, y cualquier listado aún requiere una reglamentación de avisos y comentarios. Nada ha cambiado legalmente todavía, y aparece en la lista una pregunta de estado compuesto, no es un hallazgo de seguridad.

Lo que ya se aplica no ha cambiado: bajo la sección 503A, una sustancia farmacéutica a granel necesita un certificado de análisis válido y debe provenir de un establecimiento registrado ante la FDA en la sección 510 (FDA, 2026-05-14). La FDA también describe la lista 503A como actualizada de forma continua según una política provisional con tres categorías.. Es por eso que la siguiente lista de verificación de documentación de péptidos se centra en los registros que usted controla actualmente..

Cómo utilizar esta lista de verificación de documentación de péptidos

Esta lista de verificación cubre seis áreas: identidad, pureza, métodos analíticos, perfiles de impurezas, abastecimiento, y uso previsto. Se asignan a cuatro fases de trabajo.: presíntesis, en proceso, liberar, y entrega. Cada elemento está redactado como un juicio binario., para que puedas responder si o no y seguir adelante.

Se aplican dos límites de alcance. Esta es una guía de documentación., no asesoramiento legal o regulatorio; Consulte a un asesor regulatorio calificado antes de tomar decisiones de cumplimiento.. Y el estado de la lista y el estado de seguridad son preguntas separadas.: aparecer dentro o fuera de una lista no establece por sí solo si un péptido es seguro.

Trabaja a través de las fases en orden, luego use la tabla consolidada al final para confirmar que no se perdió nada. Las secciones siguientes definen lo que se considera documentación adecuada de síntesis de péptidos personalizada para cada elemento..

Fase 1 — Registros de presíntesis y abastecimiento

Los registros más baratos de crear son los más difíciles de reconstruir posteriormente. Un número de lote escrito en un registro de recepción en el momento de la entrada tarda unos segundos.; recuperando ese mismo número de lote dieciocho meses después, cuando un compañero pregunta qué bloques de construcción se incluyeron en un lote, Puede llevar días y puede terminar en una respuesta que nadie puede defender..

Cuatro elementos pertenecen a esta fase., y cada uno es un cheque binario:

• Se registran los números de lote de resina y bloques de construcción de aminoácidos., con el CoA del proveedor archivado para cada. La trazabilidad tiene que sobrevivir a nivel de lote, no el nivel de catálogo. Un paquete de calificación del proveedor debe incluir un certificado de análisis específico del lote que registre las pruebas., especificaciones y resultados para ese lote, además de trazabilidad de lotes y SKU hasta una ruta de síntesis documentada (notas de laboratorio de lyochem, 2026-06-01). El propio esquema de la FDA sobre los requisitos de la sección 503A apunta en la misma dirección, esperando un CoA válido y un fabricante registrado 510 (FDA, 2026-05-14).

• Identidad estándar de referencia, El número de lote y el vencimiento están documentados..

• Una declaración escrita del uso previsto distingue el uso en investigación del uso compuesto.

• Se documenta la cadena de custodia desde la recepción hasta el almacenamiento..

La fecha de vencimiento del estándar de referencia es el elemento que los equipos suelen presentar en el lugar equivocado.. Pertenece al registro de lote., no en un cuaderno de laboratorio, porque el registro del lote es lo que realmente lee un revisor o socio. Si el estándar expiró antes de la ejecución, los datos de identidad generados en su contra llevan una calificación que el registro debe indicar en su anverso, y una entrada de cuaderno a tres estantes de distancia no aparecerá.

Fase 2 — Documentación de Identidad

La identidad es una cuestión separada de la pureza., y un 98% purity figure does not answer it. Purity testing confirms how much of the material elutes as the main peak; it does not confirm that the main peak is the peptide you ordered. Como Peptra Labs explains in its certificate of analysis guide, purity testing is not identity confirmation “unless an identity assay exists for that batch” (2026-05-22). That conditional wording is the whole point: identity has to be demonstrated by a method that can distinguish your sequence from a near neighbour.

Three methods carry that specificity. Mass spectrometry establishes molecular mass, with electrospray ionization tolerances of ±1 Da below 5,000 Da and ±2 Da above it, and MALDI-TOF holding ±0.5 Da on shorter peptides (Lyos Labs, 2026-04-08). Amino-acid analysis reports composition after hydrolysis, and peptide mapping locates the sequence itself. Each produces its own record: the spectrum or composition report, the expected versus observed value, the instrument and acquisition parameters, and the analyst and date.

On validation scope, the reading of ICH Q2(R2) that Peptide Staff applies to peptide methods is that identity methods do not need full validation across every characteristic, but they do need to show specificity (2026-09-11). Read that as a documentation instruction rather than a relaxation: the file still has to prove the method discriminates, which means a specificity rationale, a representative spectrum, and a stated acceptance window. This is where peptide analytical method validation expectations differ most sharply between identity and assay work, and where a thin file is easiest to spot.

Fase 3 — Documentación de pureza y qué significa el número

A CoA purity figure is an area-percent measure, and it systematically reads high. The record has to state what was measured and how, or the number invites a false conclusion about content.

The distinction is not academic. In one cited metrology example, a manufacturer-stated content of 983.72 mg/g sat against a mass-balance determination of 896.36 ± 0.68 mg/g, a gap on the order of seventy-plus milligrams per gram (lineara, 2026-05-01). Treat that as a single-upstream illustration, not a general rule.

Water and counter-ions explain much of the difference. Lyophilized peptides are hygroscopic, and failing to correct for water can bias results by several percent; Karl Fischer reports water as % w/w and feeds the net-content and salt-correction calculation (clarascience, 2026-07-15). Counter-ions such as trifluoroacetate, acetate and chloride contribute to batch mass but are not detected at 214 Nuevo Méjico (peptidetrace, 2026-05-23).

So the record must state the reporting convention: as-is, anhydrous, or salt-free. El 95%, 98% y 99%+ bands are marketing conventions rather than validated specifications; a 95% specification may contain up to 5% by weight of related substances, synthesis byproducts, residual protecting groups or counter-ions (peptidetrace, 2026-05-23).

Conclusión clave: An area-percent figure answers “how much of the UV-absorbing material is the main peak”, not “how much peptide is in the vial”.

Fase 4 — Registros de métodos analíticos

A method is only reconstructable if the file names the column, the mobile phase, el gradiente, the detection wavelength and the integration rules. Everything else is a summary that a receiving lab has to rebuild from scratch.

Conventional peptide practice records a defined parameter set. Column chemistry defaults to C18 for short and mid-length peptides, with C8 for over-retained hydrophobic sequences and 300 Å for longer chains. Dimensions are typically 4.6 × 150 mm for UV purity work and 2.1 × 100 mm for LC-MS, with pore sizes of 100-130 Å and particle sizes of 3.5 o 2.7 µm, dropping to 1.7-1.8 µm for LC-MS (reversed-phase HPLC method parameters for peptides, 2026-09-15). Mobile phases run 0.1% TFA (apenas 13 milímetro) in water and acetonitrile, switching to 0.1% formic acid for LC-MS. Gradients are scouting at 5-65% B over 60 minutes at 1.0 ml/min, or focused at 0.25-0.5% B/min, con un 90-95% B wash of at least 5 minutes and re-equilibration of about 10 column volumes. The measured dwell volume belongs in the method, and detection sits at 214 nm for the peptide bond.

Method status is a separate record from method content. A validated method has been formally demonstrated fit for its intended purpose across the relevant performance characteristics, while a qualified method is a limited demonstration of fitness for a narrower, defined purpose without the full validation evidence (peptide analytical method validation guidelines, 2026-09-11). Which characteristics apply depends on method purpose. Under the adopted Yo Q2(R2) pauta, eficaz 14 Junio 2024, the named characteristics include accuracy, precisión, especificidad, límite de detección, límite de cuantificación, linearity and range. In peptide practice, assay methods carry the full set, with a range of 80-120% of target, recovery of 98-102%, RSD at or below 2% and r² of at least 0.999. Impurity methods lean on specificity and sensitivity instead: a range from the reporting threshold to 120% of the specification limit, a limit of detection well below the reporting threshold, a limit of quantitation at or below it, and forced degradation to establish specificity. Treat those figures as peptide convention rather than as ICH requirements.

System suitability criteria and integration settings are records in their own right, not settings buried in the software. Write down the resolution, factor de cola, retention time repeatability and signal-to-noise thresholds that a run must meet before its result counts, and record Péptidos sintéticos the integration rules (baseline mode, smoothing, minimum area threshold, manual intervention and who authorised it). A purity figure produced under unstated integration rules cannot be defended, and a method that cannot be reconstructed cannot be transferred to a larger scale.

Fase 5 — Documentación del perfil de impurezas

A defensible impurity record lists the classes you looked for and the method that would have found each one. Deletion sequences show as a mass deficit for the absent residue; truncated chains sit at lower mass; oxidised methionine appears as a +16 Da satellite; deamidated Asn or Gln shifts by +1 Da with altered retention; racemisation changes activity without changing mass; TFA adducts show up directly in the chromatogram (lyoslabs, 2026-04-08). Because these species can be close in both mass and retention, a single chromatogram will not separate them all, which is why peptide purity and impurity profile documentation pairs orthogonal methods rather than one run.

Thresholds for reporting, identification and qualification trace to ICH Q3B(R2), which sets identification typically at 0.10% o 1.0 mg per day intake, whichever is lower. That framework does not apply to research-grade material in the same formal sense, so state which threshold basis your record uses.

Fase 6 — Registros de liberación y entrega

Assemble the hand-over as a package, not as a folder of files. The package is the artifact a partner actually reads, and a missing element blocks a program even when the underlying work was sound. Start with the peptide certificate of analysis requirements: the product name must match the vial label, the batch or lot must match both the vial and the order paperwork, and the report must carry the test date, the analytical method, the batch-specific purity result, the testing laboratory, and a lab-controlled public report URL rather than a supplier-hosted page alone (Peptra Labs, 2026-05-22). Producción de péptidos

Bind every reported value to the raw data behind it, and keep the version and approval trail with the record set. Records should be attributable, legible, contemporáneo, original y preciso, and the set should let a reviewer reconstruct the batch without contacting the lab.

Para propina: If a reviewer has to email you to understand a number, the package is incomplete. Acerca de

Documentation packages of this kind are the workflow Cambios de MOL supports.

Lista de verificación de documentación consolidada de péptidos

This peptide documentation checklist condenses the six coverage areas into one printable page. Each row is a binary judgment: either the record exists in the lot file or it does not. Hand it to the team before the next campaign starts, and treat any “no” as an open item rather than a formality.

Two habits keep this page useful. Primero, review it at the point each record is generated, not at release, because reconstructing an integration rule or a system suitability result months later is where most gaps appear. Segundo, keep the raw data behind every row, since a summary table without the underlying chromatogram or spectrum does not survive scrutiny.

Conclusión clave: A documentation package is only as strong as its weakest row. If any item above cannot be answered with a specific record, that is the item to fix before the next lot is released.

Preguntas comunes sobre la documentación de péptidos

¿Cuánto tiempo se debe conservar la documentación de péptidos??

Retain records for as long as the material can be in use or referenced, then add a defined margin on top of that. Because a lot may be held, re-tested, or shipped years after release, the retention period should be set by the longest plausible use window, not by the release date. Where a lot is tied to a sterility or endotoxin claim, the retention clock follows the longest applicable requirement, since those records are the ones most likely to be requested later.

What if a supplier’s certificate of analysis omits a method detail?

Ask the supplier for the missing detail in writing before you accept the lot, and record the request and the response. A certificate that reports a purity figure without naming the method, columna, or detection wavelength cannot be independently interpreted, so the gap is a documentation defect rather than a formatting preference. If the supplier will not supply it, treat the lot as unverified for that attribute and say so in your own records.

¿Es un método calificado aceptable para un propósito determinado??

Sí, provided the qualification is documented against the intended use and the limits are stated. A qualified method is acceptable when its fitness for the specific purpose has been demonstrated and recorded; it is not acceptable as a substitute for a validated method where the purpose requires validated performance. The deciding question is what the result will be used to support, not how the method was labeled.

¿Qué debemos hacer cuando muchas cosas fallan en la idoneidad del sistema??

Do not release the lot, and do not re-integrate or re-run until the failure is investigated and the cause is identified. A system suitability failure is a signal about the method or the instrument as much as about the sample, so the investigation should establish which before any repeat injection is treated as a valid result. Document the failure, the investigation, and the resolution together, because the failed run is part of the lot’s record.

Conclusión clave: Each answer above stands alone, so you can lift the one you need into a supplier query, an SOP note, or a review meeting without losing its context.

Próximos pasos

The regulatory outcome is not yours to control; the record set is. Start tomorrow with the phase that is weakest in your current files, usually Phase 4, and work forward. A peptide documentation checklist only helps if someone can hand the file to a reviewer who was not in the room.

If you would like a worked example, MOL Changes supports teams with a sample documentation package covering method files, impurity tables and lot-level release records, which can be used to benchmark your own template before your next audit cycle.

This article is documentation guidance, no asesoramiento legal o regulatorio. Consult qualified regulatory counsel before making compliance decisions. Reviewed by the MOL Changes technical documentation team. MOL Changes provides custom peptide synthesis and analytical services; this article is educational and does not constitute a product recommendation.